Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Sinovac Biotech Stories

2012-03-21 02:24:37

BEIJING, March 21, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccines in China, today announced that it will release its unaudited financial results for the fourth quarter ended December 31, 2011 before market on Thursday, March 29, 2012. The Company will host a conference call on Thursday, March 29, 2012 at 8:00 a.m. EDT (March 29, 2012 at 8:00 p.m. China Standard Time) to review the Company's financial results and provide an update on recent...

2012-01-24 15:05:00

BEIJING, Jan. 24, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccines in China, today announced that it received a letter dated January 18, 2012 from The Nasdaq Stock Market. Based on the departure of Ms. Chup Hung Mok from the Company's Board of Directors effective January 4, 2012, Nasdaq has determined that the Company no longer complies with Nasdaq's requirement that its audit committee consists of at least three independent directors, as set forth...

2012-01-10 07:00:00

BEIJING, Jan. 10, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of biopharmaceutical products in China, announced today that the phase III clinical trial for its proprietary inactivated EV71 vaccine against hand, foot and mouth disease (HFMD) has begun. The Phase II trial, completed in November 2011, confirmed favorable safety and tolerance profiles, and good immunogenicity. According to the results of phase II clinical trial, the formulation of 400U with...

2012-01-04 07:00:00

BEIJING, Jan. 4, 2012 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccines in China, today announced the resignation of Ms. Chup Hung Mok from its Board of Directors for personal reasons. The Board has commenced a search for a replacement director and is considering a few candidates. Sinovac will make the appropriate announcement in due course when it appoints a new director. Dr. Weidong Yin, Chairman and CEO, stated, "We would like to thank Cathy for...

2011-11-23 07:00:00

BEIJING, Nov. 23, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccines in China, today announced that management is scheduled to present at the 23rd Annual Piper Jaffray Health Care Conference that will be held on November 29th and 30th at The New York Palace in New York City, and to participate in HK/China Mini Conference 2011 (Healthcare) on December 1, 2011 at Island Shangri-La Hotel, Hong Kong. Ms. Helen Yang, Sinovac's Investor Relations...

2011-11-16 08:32:00

BEIJING, Nov. 16, 2011 /PRNewswire-Asia/ -- In the news release, "Sinovac Reports Unaudited Third Quarter 2011 Financial Results" with financial tables, issued on November 14, 2011 by Sinovac Biotech Ltd. over PR Newswire, we are advised by the Company that the third sentence of the fourth paragraph from the section titled "Financial Review for Third Quarter Ended September 30, 2011" should be read as " Excluding pandemic flu vaccine sales, SG&A as a percentage of sales was 57.7% and...

2011-11-14 06:09:00

BEIJING, Nov. 14, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today its unaudited third quarter financial results for the period ended September 30, 2011. Financial Highlights Sales in the third quarter increased 60.8% year-over-year to $15.4 million, compared to $9.6 million, and year-to-date sales increased 47.2% to $35.7 million. Net loss attributable to stockholders in the third...

2011-11-09 07:00:00

BEIJING, Nov. 9, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today the positive top-line results from its phase II clinical trial for its proprietary inactivated vaccine against human enterovirus 71 (EV71), which causes hand, foot and mouth disease (HFMD). The preliminary Phase II results for the EV71 vaccine showed a good immunogenicity and a favorable safety profile with no vaccine-related serious...

2011-11-08 07:00:00

BEIJING, Nov. 8, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccines in China, today announced that management is scheduled to present at the Cowen and Company China Opportunity Conference that will be held on November 15 - 16 at The St. Regis Beijing. The Sinovac team, inclusive of Dr. Weidong Yin, Chairman and CEO, Ms. Helen Yang, Investor Relations Director and Chris Lee, Investor Relations, will participate in the Biopharmaceuticals Panel at...

2011-11-07 07:00:00

BEIJING, Nov. 7, 2011 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading provider of vaccines in China, today announced that it will release its unaudited financial results for the third quarter ended September 30, 2011 before market open on Monday, November 14, 2011. The Company will host a conference call on Monday, November 14, 2011 at 8:00 a.m. EST (November 14, 2011 at 9:00 pm China Standard Time) to review the Company's financial results and provide an update on recent...